Manufacturers’ Roulette unlikely to pay a second time
Banking on pandemics is a bit like betting green at the Roulette table. It doesn’t hit often, but when it does hit, there’s a big payout.
By all accounts, it’s been a very busy first half of the season for cough-cold manufacturers, even though the 52-week comparable period is only showing a 1.9% lift in overall sales across food, drug and mass (minus Walmart) for the period ended Jan. 24, according to Information Resources Inc. data.
For the 2009-2010 season, the weekly percentage of outpatient visits for influenza-like illness peaked at the end of October 2009 at 7.7%, the Centers for Disease Control and Prevention reported. That peak was higher than the three previous influenza seasons as reported by the U.S. Outpatient ILI Surveillance Network. The percentage of outpatient visits for flu decreased to 1.8% at the beginning of January. The number of states reporting widespread influenza activity dropped from 49 at the end of October 2009 to zero at the beginning of January.
Top 10 cold/allergy/ sinus liquids/powders
Encompassing cough drops and cough syrups—as well as cough/allergy/sinus tablets, liquids and powders—sales across these four broad categories totaled $4.1 billion in that period, representing $75.8 million in incremental sales versus the prior year.
Some of the big winners across cough-cold in the past year included Reckitt Benckiser and Novartis Consumer Healthcare. Reckitt Benckiser realized $12.7 million in incremental sales across its Delsym brand for the year (sales $88.1 million, up 16.8%) and $9.4 million across Mucinex D, sold exclusively behind the pharmacy counter (sales $80.4 million, up 13.3%). And Novartis’ Theraflu brand performed exceptionally well, with $8.3 million in incremental dollars across Theraflu liquids ($33 million, up 33.7%) and $10.2 million incremental dollars across Theraflu tablets ($78.6 million, up 14.9%).
Top 10 cold/allergy/sinus tablets
Manufacturers of homeopathic cough-cold remedies, in particular, have realized significant sales gains. Sales of Matrixx’ Zicam tablets were up 14.1% to $44.7 million. And within sales of cough syrups, both Boiron and Hyland’s cracked the top 10 list of cough syrup manufacturers, with sales of $1.8 million (up 436.3%) and $1.2 million (84.4%), respectively. Add into the mix Walmart, and he numbers become more substantial, one homeopathic manufacturer noted, as distribution was expanded from 350 Walmart locations last year to more than 3,200 this year.
Top 10 cough drop vendors (primary brand in parentheses)
|Cadbury Adams (Halls)||$171.8||0.7%|
|Quigley (Cold Eeze)||23.3||-13.1|
|McNeil Consumer (Luden’s)||20.4||4.3|
|Prestige brands (Chloraseptic)||13.7||-9.6|
|Insight Pharmaceuticals (Sucrets)||9.1||-9.0|
|Lofthouse of Fleetwood (Fisherman’s Friend)||4.0||7.6|
For Boiron, some of that triple-digit growth can be traced to increased distribution, “but more of it was the fact that our lead product Oscillococcinum is indicated for the treatment of flu-like symptoms,” John Durkin, Boiron VP sales and marketing, told Drug Store News. “We had done a lot of branding on that product with an advertising and PR campaign.” Sales of Oscillo certainly were linked to incidence of H1N1, Durkin noted, as sales were very strong beginning with the initial reports of H1N1 incidence in March/April of last year through the end of the year.
Top 10 cough syrup vendors (primary brand in parentheses)
|Pfizer Consumer (Robitussin)||$149.4||14.2%|
|Reckitt Benckiser (Delsym)||89.7||2.0|
|Procter & Gamble (Vicks NyQuil)||33.0||33.7|
|Novartis Consumer (Triaminic)||31.8||7.8|
|Health Care Products (Diabetic Tussin)||30.0||17.6|
|Qualitest Products (Cheratussin AC)||27.7||-18.0|
|Matrixx Initiatives (Zicam)||26.5||6.4|
|McNiel Consumer (Zyrtec)||25.0||5.9|
|Boiron (Children’s Chestal)||22.9||18.0|
“Homeopathic cough-cold medicines have experienced a substantial increase in sales and market share in the last two or three years in the United States,” acknowledged Dale Nepsa, president of Hyland’s. “Much of this increase has been in the pediatric sector due to concerns for safety and efficacy of some allopathic brands. More recently, concerns surrounding the H1N1 virus, along with a shortage of vaccine, have had a positive impact on the trial and sales of homeopathic OTC offerings.”
So the question for retailers and suppliers looking forward to the 2010-2011 is, what are the chances the Roulette wheel falls into cough-cold green again?
The odds are not very likely, especially given the fact that the H1N1 vaccine might be folded into next season’s triumvirate seasonal vaccine. That suggests that even if the novel H1N1 flu does continue to make its course through America, there won’t be nearly the media attention paid to it next year that there was this year.
Such being the case, that may prompt many purveyors of cold medicines to revert back to historical inventory buys. With both SKU rationalization programs and the number of consecutive soft cold-and-flu seasons leading up to 2009-2010, that likely means a significant drop-off in supply to match an expected drop-off in demand.
That scaling back in cough-cold inventory commitments already is being realized. “As a result of retailers stocking up in anticipation of the H1N1 outbreak this past fall, inventory levels at retail are very high,” noted Bill Hemelt, Matrixx Initiatives president, CFO and COO, during an analyst call in late January. Hemelt suggested that inventory sales for the second-half of the cough-cold season—now through the end of May—will be much lower as a result.
As of press time, at least with Matrixx, retailers were carrying approximately five additional weeks of inventory as compared with late January/early February 2009. The plan right now is to sell through that excess inventory through the rest of the season, Hemelt said. “The H1N1 effect for retailers, which was really the biggest effect, was the fact that they bought so much inventory in August, September and October,” Hemelt said. “It finally caught up to them in December, and they stopped purchasing in large quantities. Their goal is to get back down to the same level they were at last March. And we think that they should be able to do that with a normal type of cold season.”
Barring a steady rate of H1N1-related illness over the summer, as there was in 2009, the other wildcard that purveyors of cough-cold medicines may want to consider as they begin planning for next year is the evolving shopping patterns thanks to a recession economy. There are two factors associated with the economy that could help boost sales of nonprescription cough-cold medicines. First, more consumers are looking for cheaper alternatives in their healthcare expenditures, a factor that may drive more consumers to seek symptomatic relief of their flu or colds before scheduling an appointment with their doctors or at the local retail clinic. In addition, more workers are declining to take off from work when they’re sick, either to recover from that cold or flu or to visit the doctor’s office (see story on page 43).
“Moms are concerned about not going to work,” Durkin confirmed, referencing Boiron’s own internal consumer research. “You have a lot of working moms, [and] we are in tough economic times and there is a lot of stress on the family.”
Bashas’ rejects Albertsons’ buyout bid
NEW YORK Bashas’ has turned down a nearly $300 million buyout offer from Albertsons, according to published reports.
According to an American City Business Journals article, the Chandler, Ariz.-based Bashas’ was uninterested in a buyout offer of $290 million for the chain.
Bashas’ filed for Chapter 11 bankruptcy protection in July, announcing the following month that it would close 14 stores. Still, the published reports quoted an attorney representing the company as saying that the reorganization plan would ensure Bashas’ remained in the hands of the Bashas family, which has owned it since 1932.
Shoppers’ new initiatives sets chain up to become retail giant
WHAT IT MEANS AND WHY IT’S IMPORTANT While the decision to move in this direction may have been made before Chong Bang crossed the border, there is no questioning that industry watchers will be focused on what SDM’s new top merchant will do to further improve the stores.
(THE NEWS: Shoppers Drug Mart takes a page out of CCR playbook. For the full story, click here)
That has a lot to do with Bang’s pedigree — he’s directed a significant merchandising program at Walgreens, one of the leading pureplay pharmacies in the United States. And now he’s at Shoppers, the leading drug store retailer north of the border.
Bang will be armed at Shoppers with the sales data generated by 9.7 million members of the pharmacy’s Optimum loyalty program, 80% of whom are women. When you consider that there are only 34 million Canadians, that means that almost 1-in-3 Canadians are members of Shoppers’ loyalty program, and almost 1-in-2 Canadian women.
Presently, Shoppers plans to grow its square footage at a clip of 8% to 9% with a new distribution center slated to open in 2010 to help support that growth. And that’s really going to be Bang’s merchandising challenge — finding a way to slip one more item into that Shoppers marketbasket in a saturated marketplace. Bang certainly can’t build front-end sales by attracting new customers. There just aren’t that many Canadians who don’t already shop at Shoppers.
For Bang, it’ll be a question of optimizing categorical synergies and in doing so help drive impulse purchases. Similar to Walgreens, Shoppers is on a mission to make a good shopping experience better, and Bang’s expected to help realize that goal.